GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (LSE:POLB) » Definitions » Long-Term Debt

Poolbeg Pharma (LSE:POLB) Long-Term Debt : £0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Poolbeg Pharma Long-Term Debt?

Poolbeg Pharma's Long-Term Debt for the quarter that ended in Jun. 2024 was £0.00 Mil.


Poolbeg Pharma Long-Term Debt Historical Data

The historical data trend for Poolbeg Pharma's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma Long-Term Debt Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23
Long-Term Debt
- - -

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Long-Term Debt Get a 7-Day Free Trial - - - - -

Poolbeg Pharma  (LSE:POLB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.


Poolbeg Pharma Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Poolbeg Pharma Business Description

Traded in Other Exchanges
Address
42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX
Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.

Poolbeg Pharma Headlines

No Headlines